Mechanisms of obesity-associated cardiovascular and renal disease

American Journal of the Medical Sciences

Volumn 324, Issue 3, 2002, Pages 127-137

  Hall, John E ^a,b   Crook, Errol D ^c   Jones, Daniel W ^a,b   Wofford, Marion R ^a,b   Dubbert, Patricia M ^b  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic renal disease; Heart; Hypertension; Kidney; Sympathetic nervous system; Type 2 diabetes

Indexed keywords

C REACTIVE PROTEIN; HORMONE; INTERLEUKIN 6; LEPTIN; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; EPIDEMIC; EXTRACELLULAR SPACE; GENOMICS; GLOMERULUS FILTRATION; HEART FUNCTION; HEART VENTRICLE HYPERTROPHY; HEMODYNAMIC MONITORING; HUMAN; HYPERCOAGULABILITY; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY DISEASE; KIDNEY TUBULE ABSORPTION; NONHUMAN; OBESITY; PROTEIN FUNCTION; PROTEOMICS; SYMPATHETIC TONE; SYSTOLIC BLOOD PRESSURE; THROMBOSIS; WEIGHT GAIN;

EID: 0036745457     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200209000-00003     Document Type: Article

References (79)

1. Reavan GM. Role of insulin resistance in human disease (Syndrome X): an expanded definition. Annu Rev Med 1993;44:121-31.
2. Landsberg L. Insulin and hypertension: Lessons from obesity. N Eng J Med 1987;317:378-9.
3. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. NIH Publication No. 98-4083. Bethesda (MD): National Heart, Lung, and Blood Institute in cooperation with The National Institute of Diabetes and Digestive and Kidney Diseases; 1998.
4. Najjar M, Rowland M. Anthropometric reference data and prevalence of overweight United States 1976-1980; Vital and Health Statistics of the U.S. Department of Health and Human Services (DHHS). DHHS publication No. (PHS) 87-1688. Hyattsville (MD): National Center for Health Statistics, Public Health Service, US Department of Health and Human Services; 1987.
5. Stamler J. Epidemic obesity in the United States. Arch Intern Med 1993;153:1040-4.
6. Flegal KM, Carroll MD, Kuczmarski RJ, et al. Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord 1998;22:39-47.
7. Kumanyika S. Obesity in black women. Epidemiol Rev 1987;9:31-50.
8. Alexander J, Dustan HP, Sims EAH, et al. Report of the Hypertension Task Force. Department of Health Education and Welfare publication no (DHEW) 70-1631. Washington DC: US Department of Health, Education, and Welfare; 1979. p. 61-77.
9. Jones DW, Kim JS, Andrew ME, et al. Body mass index and blood pressures in Korean men and women: the Korean National Blood Pressure Survey. J Hypertens 1994;12:1433-7.
10. Garrison RJ, Kannel WB, Stokes J, et al. Incidence and precursors of hypertension in young adults: the Framingham Offspring Study. Prevent Med 1987;16:234-51.
11. Cignolini M, Seidell JC, Targher JP, et al. Fasting serum insulin in relation to components of the metabolic syndrome in European healthy men: the European fat distribution study. Metabolism 1995;44:35-40.
12. Cooper RS, Potimi CN, Ward R. The puzzle of hypertension in African-Americans. Sci Am 1999;280:56-63.
13. Reisen E, Abel R, Modan M, et al. Effect of weight loss without salt restriction on the reduction of blood pressure in overweight hypertensive patients. New Engl J Med 1978;198:1-6.
14. Hall JE, Brands MW, Dixon WN, et al. Obesity-induced hypertension: renal function and systemic hemodynamics. Hypertension 1993;22:292-9.
15. Carroll JF, Huang M, Hester RL, et al. Hemodynamic alterations in obese rabbits. Hypertension 1995;26:465-70.
16. Rocchini AP, Mao HZ, Babu K, et al. Clonidine prevents insulin resistance and hypertension in obese dogs. Hypertension 1999;33:548-53.
17. Dobrian AD, Davies MJ, Prewitt RL et al. Development of a rat model of diet-induced obesity. Hypertension 2000;35:1009-15.
18. Hall JE. Pathophysiology of obesity hypertension. Curr Hypertens Rep 2000;2:139-47.
19. Messerli FH, Christie B, DeCarvalho JG, et al. Obesity and essential hypertension. Hemodynamics, intravascular volume, sodium excretion and plasma renin activity. Arch Intern Med 1981;141:81-85.
20. Van Vliet BN, Hall JE, Mizelle HL, et al. Reduced parasympathetic control of heart rate in obese dogs. Am J Physiol 1995;269:H629-37.
21. Verwaerde P, Senard JM, Galinier M, et al. Changes in short-term variability of blood pressure and heart rate during the development of obesity-associated hypertension in high-fat fed dogs. J Hypertens 1999;17:1135-43.
22. Arone LJ, Mackintosh R, Rosenbaum M, et al. Autonomic nervous system activity in weight gain and weight loss. Am J Physiol 1995;269:R222-5.
23. Rocchini AP. The influence of obesity in hypertension. News Physiol Sci 1990;5:245-9.
24. Reisin E, Messerli FH, Ventura HO, et al. Renal hemodynamics in obese and lean essential hypertensive patients. In: Messerli FH, editor. Kidney in essential hypertension. Boston: Martinus Nihoff; 1984. p. 125-9.
25. Hall JE. Renal and cardiovascular mechanisms of hypertension in obesity. Hypertension 1994;23:381-94.
26. Carroll JF, Braden DS, Cockrell K, et al. Obese rabbits develop concentric and eccentric hypertrophy and diastolic filling abnormalities. Am J Hypertens 1997;10:230-3.
27. Gottdiener JS, Reda DJ, Materson BJ, et al. Importance of obesity, race and age to the cardiac structural and functional effects of hypertension. J Am Coll Cardiol 1994;24:1492-8.
28. Alpert MA, Hashimi MW. Obesity and the heart. Am J Med Sci 1993;306:117-23.
29. Carroll JF, Braden DS, Henegar JR, et al. Dietary sodium chloride (NaCl) worsens obesity-related cardiac hypertrophy [abstract]. FASEB J. 1998;12:A708
30. Carroll JF, Summers RL, Dzielak DJ, et al. Diastolic compliance is reduced in obese rabbits. Hypertension 1999;33:811-5.
31. Carroll JF. Post-beta receptor defect in isolated hearts of obese-hypertensive rabbits. Int J Obes Relat Metab Disord 1999;23:863-6.
32. Alexander JK, Peterson KL. Cardiovascular effects of weight reduction. Circulation 1972;45:310-8.
33. Alpert MA. Management of obesity cardiomyopathy. Am J Med Sci 2001;32:237-41.
34. Hall JE, Hildebrandt DA, Kuo J. Obesity hypertension: role of leptin and the sympathetic nervous system. Am J Hypertens 2001;14:103S-15S.
35. Hall JE, Brands MW, Henegar JR. Mechanisms of hypertension and kidney disease in obesity. Ann N Y Acad Sci 1999;892:91-107.
36. Hall JE. Mechanisms of abnormal renal sodium handling in obesity hypertension. Am J Hypertens 1997;10:S49-S55.
37. Landsberg L, Krieger DR. Obesity, metabolism, and the sympathetic nervous system. Am J Hypertens 1989;2:1255-325.
38. Tuck ML, Sowers J, Dornfield L, et al. The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med 1981;304:930-3.
39. Rumantir MS, Vaz M, Jennings GL, et al. Neural mechanisms in human obesity-related hypertension. J Hypertens 1999;17:1125-33.
40. Esler M. The sympathetic system and hypertension. Am J Hypertens 2000;13:99S-105S.
41. Wofford MR, Anderson DC, Brown CA, et al. Antihypertensive effect of alpha and beta adrenergic blockade in obese and lean hypertensive subjects. Am J Hypertens 2001;14:694-8.
42. Kassab S, Kato T, Wilkins C, et al. Renal denervation attenuates the sodium retention and hypertension associated with obesity. Hypertension 1995;25:893-7.
43. Weyer C, Pratley RE, Snitker S, et al. Ethnic differences in insulinemia and sympathetic tone as links between obesity and blood pressure. Hypertension 2000;36:531-7.
44. Abate NI, Mansour YH, Arbique D, et al. Overweight and sympathetic activity in black Americans. Hypertension 2001;38:379-83.
45. Hall JE, Shek EW, Brands MW. Is leptin a link between obesity and hypertension? Curr Opin Endocrinol Diabetes 1999;6:225-9.
46. Haynes WG, Sivitz WI, Morgan DA, et al. Sympathetic and cardiorenal actions of leptin. Hypertension 1997;30:619-23.
47. Haynes WG, Morgan DA, Walsh SA, et al. Cardiovascular consequences of obesity: role of leptin. Clin Exp Pharmacol Physiol 1998;25:65-9.
48. Flier JS. Clinical review 94: What’s in a name? In search of leptin’s physiologic role. J Clin Endocrinol Metab 1998;83:1407-13.
49. Flier JS, Maratos-Flier E. Obesity and the hypothalamus: novel peptides for new pathways. Cell 1998;92:437-44.
50. Considine RV. Regulation of leptin production. Rev Endocr Metab Disord 2001;2:357-63.
51. Ruhl CE, Everhart JE. Leptin concentrations in the United States: relations with demographic and anthropometric measures. Am J Clin Nutr 2001;74:295-301.
52. Casto RM, VanNess JM, Overton JM. Effects of central leptin administration on blood pressure in normotensive rats. Neurosci Lett 1998;246:29-32.
53. Shek EW, Brands MW, Hall JE. Chronic leptin infusion increases arterial pressure. Hypertension 1998;31:409-14.
54. Kuo JJ, Jones OB, Hall JE. Inhibition of NO synthesis enhances chronic cardiovascular and renal actions of leptin. Hypertension 2001;37:670-6.
55. Aizawa-Abe M, Ogawa Y, Mazuzaki H, et al. Pathophysiological role of leptin in obesity related hypertension. J Clin Invest 2000;1243-52.
56. Carlyle M, Jones OB, Kuo JJ, et al. Chronic cardiovascular and renal actions of leptin-role of adrenergic activity. Hypertension 2002;39:496-501.
57. Mark AL, Shaffer RA, Correia ML, et al. Contrasting blood pressure effects of obesity in leptin-deficient ob/ob mice and agouti yellow mice. J Hypertension 1999;17:1949-53.
58. Rahmouni K, Haynes WG, Morgan DA, et al. Selective resistance to central administration of leptin in agouti mice [abstract]. Hypertension 2001;38:506.
59. Sugarman HJ, Windsor ACJ, Bessos MK, et al. Intra-abdominal pressure, saggital abdominal diameter and obesity co-morbidity. J Intern Med 1997;241:71-79.
60. Bloomfield GL, Sugerman HJ, Blocher CR, et al. Chronically increased intra-abdominal pressure produced systemic hypertension in dogs. Int J Obes Relat Metab Disord 2000;24:819-24.
61. Kissebah AH, Krakower GR. Regional adiposity and morbibity. Physiol Rev 1994;74:761-811.
62. Sundquist J, Winkeby MA, Pudaric S. Cardiovascular disease risk factors among older black, Mexican-American, and white women and men: an analysis of NHANES III; 1988-1994. J Am Geriatr Soc 2001;49:109-16.
63. Okosun ISA, Choi S, Dent MM, et al. Abdominal obesity defined as a larger than expected girth is associated with racial/ethnic differences in the risk of hypertension. J Hum Hypertens 2001;15:307-12.
64. Stern JS, Gades MD, Wheeldon CM, et al. Calorie restriction in obesity: prevention of kidney disease in rodents. J Nutr 2001;131:913S-7S.
65. Reisin E, Azars, DeBoisblanc BP et al. Low calorie unrestricted protein diet attenuates renal injury in hypertensive rats. Hypertension 1993;21:971-4.
66. U. S. Renal Data System. USRDS 2001 annual data report: atlas of end-stage renal disease in the United States. Bethesda (MD): National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2001.
67. Wesson DE, Kurtzman NA, Prommer JP. Massive obesity and nephrotic proteinuria with a normal renal biopsy. Nephron 1985;40:235-7.
68. Henegar JR, Bigler SA, Henegar LK, et al. Functional and structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol 2001;12:1211-7.
69. Weisinger JR, Kempson RL, Eldridge L et al. The nephrotic syndrome: a complication of massive obesity. Ann Intern Med 1974;81:440-7.
70. Kambham N, Markowitz GS, Valeri AM, et al. Obesity related glomerulopathy: an emerging epidemic. Kidney Int 2001;59:1498-509.
71. Assmann G, Schulte H. The Prospective Cardiovascular Munster Study (PROCAM): prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary artery disease. Am Heart J 1988;1116:1713-24.
72. Pugh JA, Medina RA, Cornell JC et al. NIDDM is the major cause of end-stage renal disease. More evidence from a tri-ethnic population. Diabetes 1995;44:1375-80.
73. Festa A, D’Agostino R Jr, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS), Circulation 2000;102:42-47.
74. Das UN. Is obesity an inflammatory condition? Nutrition 2001;17:953-66.
75. Engeli S, Negrel R, Sharma AM. Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension 2000;35:1270-7.
76. Chu NF, Spiegelman D, Hotamisligil GS, et al. Plasma insulin, leptin, and soluble TNF receptors levels in relation to obesity-related atherogenic and thrombogenic cardiovascular disease factors among men. Atherosclerosis 2001;157:495-503.
77. Alessai MC, Morange P, Juhan-Vague I. Fat cell function and fibrinolysis. Horm Metab Res 2000;32:504-8.
78. Rissanen P, Vahtera E, Krusius T, et al. Weight change and blood coagulability and fibrinolysis in healthy obese women. Int J Obes Relat Metab Disord 2001;25:212-8
79. Konstantinides S, Schafer K, Loskutoff DJ. The prothrombotic effects of leptin-possible implications for the risk of cardiovascular disease in obesity. Ann N Y Acad Sci 2001;947:134-41.